Biond Biologics to Present at the Raymond James LILRB/ILT Symposium
Biond Biologics is a clinical stage company focused on developing innovative therapies for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics.
- Biond Biologics is a clinical stage company focused on developing innovative therapies for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics.
- Biond aims to translate high quality science and out-of-the-box disruptive thinking into transformational drugs for diseases with high unmet needs.
- The company's vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies.
- The company is also developing BND-35 an ILT3 blocking antibody, that targets suppressive myeloid cells in the tumor microenvironment.